Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)

June 22, 2026 6:58 AM
H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and $50.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments